Evaluation of the impact of minimal residual disease on overall survival, and FLT3 mutation status in FLT3 mutation-positive patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the chrysalis phase 1/2 study

被引：0

作者：

Roellig, C. ^{[1
]}

Levis, M. ^{[2
]}

Perl, A. ^{[3
]}

Altman, J. ^{[4
]}

Cortes, J. E. ^{[5
]}

Smith, C. ^{[6
]}

Baer, M. ^{[7
]}

Claxton, D. ^{[8
]}

Jurcic, J. ^{[9
]}

Ritchie, E. ^{[10
]}

Strickland, S. ^{[11
]}

Tibes, R. ^{[12
,13
]}

Hill, J. ^{[14
]}

Liu, S. ^{[14
]}

Bahceci, E. ^{[14
]}

机构：

[1] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany

[2] Johns Hopkins Univ, Adult Leukemia Serv, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[3] Univ Penn, Abramson Canc Ctr, Div Hematol Oncol, Philadelphia, PA 19104 USA

[4] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD 21201 USA

[8] Penn State Milton S Hershey Med Ctr, Hershey, PA USA

[9] Columbia Univ, Med Ctr, Dept Med, New York, NY USA

[10] Weill Cornell Med Coll, Dept Hematol Oncol, New York, NY USA

[11] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[12] Julius Maximilians Univ, Wurzburg, Germany

[13] Mayo Clin Arizona, Dept Med, Phoenix, AZ USA

[14] Astellas Pharma US Inc, Northbrook, IL USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V420

引用

页码：141 / 141

页数：1